Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Understanding IGF-1: Jefferson Researcher Sees Drug Potential in Targeting Enzyme

21.09.2005


He has labored for years over trying to understand and detail the behavior of insulin-like growth factor-1 (IGF-1) receptor, a protein which plays an important role in tumor growth. Several years ago he and his co-workers discovered that normal cells lacking the IGF-1 receptor gene could not be made to turn cancerous. He found that when they “knocked out” IGF-1 receptors in cancer cells, the cells self-destructed, meaning the IGF-1 receptor was somehow necessary for tumor cell growth. Companies are interested in targeting the IGF-1 receptor with the idea of killing cancer cells, he says.



According to Dr. Baserga, who is professor of microbiology and immunology at Jefferson Medical College of Thomas Jefferson University in Philadelphia and acting director of Jefferson’s Kimmel Cancer Center, in the past few years, scientists have learned that the IGF-1 receptor is also a key growth factor that regulates cell and body size. Deleting the genes for the IGF-1 receptor and its docking protein IRS-1 result in mouse and fly embryos that are only 50 percent of normal size.

“This tells you in essence that the IGF-1 receptor and its docking protein control 50 percent of body size in a non-redundant way,” he says. “This was an important finding because it established the role of IGF-1 receptor and IRS-1 in controlling body size.”
Reporting August 19, 2005 in the Journal of Biological Chemistry, Dr. Baserga and his co-workers provide one possible molecular explanation for how this occurs.



They found that when IRS-1 is activated with the IGF-1 receptor, ß-catenin, a protein important in colon and breast cancer is turned on. “We’re the first ones to discover that IRS-1 goes to the cell nucleus, where it binds a protein, ß-catenin, in the nucleus that regulates RNA polymerase 1, the enzyme that controls cell size,” he explains.

He doesn’t think that IRS-1 is the exclusive activator, but rather, one of several. “It makes sense,” he says. “When you knock out the IRS-1 gene, you get flies that are 50 percent in size, so there are other ways to make cells proliferate. Cells without the IGF-1 receptor can grow.”

Several years ago, Dr. Baserga, who pioneered much of the understanding of the basic behavior of the IGF-1 receptor, and his co-workers used knockouts – specially bred mice lacking a particular gene – to develop a cell line without IGF-1 receptors. Normal cells grew, but would not turn cancerous when placed in rodent cells with added cancer-causing genes.

The finding suggested that if cells that lacked IGF-1 receptor could not be turned cancerous, perhaps cancerous cells with IGF-1 could be reversed. “If this is true in humans, then this is a rational target,” he says. Studies by companies in the last few years have found that antibodies and various small molecules made to the IGF-1 receptor kill cancer cells without toxicity, he notes.

“The general idea is that if you find something that knocks out the IGF-1 receptor, you will kill the cancer cells and have only a modest effect on normal cells – at least using cells in culture and in mice,” he says. Several years ago, for example, Dr. Baserga and his group used antisense therapy to target the IGF-1 receptor, which killed cancer cells in mice but didn’t work as well in people. However, clinical trials are just beginning, he says, and he is still hopeful that other approaches will work in humans.

In the meantime, pharmaceutical companies continue to pursue potential drugs and small molecules that target the IGF-1 receptor, and still seek Dr. Baserga’s help.

Steve Benowitz | EurekAlert!
Further information:
http://www.jefferson.edu

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>